AARD — Q2 2026 Financial Report Analysis

Aardvark Therapeutics' second quarter of 2026 was the first full quarter after its drug program stalled, and the numbers show a company switching from running trials to preserving cash. Its net loss of $14.4 million was essentially the same as a year earlier, but for a different reason: trial spending fell because the trials stopped, while overhead rose on severance and bonuses paid before a workforce reduction. Aardvark has no product revenue. Its only drug in clinical testing, ARD-101, has been on a full FDA clinical hold since May 2026, and in June the company terminated its Phase 3 trial.

At a glance

• $0 revenue, $14.4M net loss ($0.66 per share), the same as Q2 2025 ($14.4M, $0.66). The flat result hides a shift in spending: research costs fell 20% while administrative costs rose 71%.
• $73.9M in cash and short-term investments at June 30, down from $91.2M at March 31 and $110.0M at the end of 2025. That is $17.3M used in the quarter and about $36M so far this year.
• Cash runway extended to "late 2027", from "mid-2027" in May and "the second quarter of 2027" in March. The runway (how long current cash can fund operations) got longer while the cash pile got smaller, because the company is now doing less.

What happened to the drug program

ARD-101 is an oral pill meant to reduce hunger by triggering bitter-taste receptors in the gut, which release natural fullness hormones. The main target was hyperphagia (constant, extreme hunger) in Prader-Willi Syndrome (PWS), a rare genetic disorder. The 10-Q gives this timeline:

• January 2026: the Phase 3 HERO trial had passed 50% of its 90-patient enrollment target.
• February 27, 2026: Aardvark voluntarily paused dosing in HERO, in its open-label extension (OLE), and in the POWER and STRENGTH trials of ARD-201, a combination product that contains ARD-101. The cause was "reversible cardiac observations in a healthy volunteer study." The filing adds that these observations "were not reported as serious adverse events."
• May 2026: the FDA placed a full clinical hold on ARD-101, meaning no clinical studies can run under its application until the FDA lifts it. The agency also set out "required human safety studies" that must be done first.
• June 2026: Aardvark terminated HERO and the OLE. It "do[es] not currently intend to resume these clinical trials as previously designed" and is reducing staff.

Management says it is analysing the unblinded HERO and OLE data this quarter (Q3 2026). "Unblinded" means researchers can now see which patients received the drug and which received placebo. Continuing the program depends on four conditions the company lists itself: the FDA lifting the hold, FDA agreement on a new trial design, supportive results from the HERO data, and raising enough money to pay for it. ARD-201 depends on ARD-101's hold being resolved.